Table 3. Univariate and multivariate analysis for cancer-specific survival and disease-free urvivlal.
Cancer-specific survival |
Disease-free survival |
|||||
---|---|---|---|---|---|---|
|
Univariate |
Multivariate |
Univariate |
Multivariate |
||
Variable | P-value | HR (95% CI) | P-value | P-value | HR (95% CI) | P-value |
Age (years) | ||||||
⩽54 | ||||||
>54 |
0.063 |
— |
— |
0.218 |
— |
— |
FIGO stage | ||||||
I | 1.000 | < 0.001 | 1.000 | < 0.001 | ||
II | 2.518 (0.819–7.743) | 0.107 | 2.659 (0.865–8.175) | 0.088 | ||
III–IV |
< 0.001 |
6.783 (2.496–18.434) |
< 0.001 |
< 0.001 |
7.213 (2.652–19.618) |
< 0.001 |
Histologic grade | ||||||
G1/G2 | 1.000 | 1.000 | ||||
G3 |
0.040 |
1.362 (0.980–1.892) |
0.066 |
0.040 |
1.446 (1.043–2.005) |
0.027 |
Histological type | ||||||
Serous | ||||||
Mucinous | ||||||
Endometrioid | ||||||
Clear cell |
0.082 |
— |
— |
0.052 |
— |
— |
Residual tumour size | ||||||
⩽1 cm | 1.000 | 1.000 | ||||
>1 cm |
< 0.001 |
1.995 (1.340–2.972) |
0.001 |
< 0.001 |
1.777 (1.197–2.637) |
0.004 |
Ascites | ||||||
⩽100 ml | ||||||
>100 ml |
0.464 |
— |
— |
0.799 |
— |
— |
Serum CA-125 level | ||||||
⩽35 U ml−1 | ||||||
>35 U ml−1 |
0.216 |
— |
— |
0.189 |
— |
— |
TNFAIP8 expression | ||||||
Low | 1.000 | 1.000 | ||||
High | < 0.001 | 1.852 (1.322–2.594) | < 0.001 | < 0.001 | 1.724 (1.235–2.407) | 0.001 |
Abbreviations: FIGO=International Federation of Gynecology and Obstetrics; HR=hazard ratio; CI=confidence interval; TNFAIP8=tumour necrosis factor-α-induced protein 8.